Last reviewed · How we verify
NCT04904874
Intense Pulsed Light Therapy in Meibomian Gland Dysfunction
NA trial testing intense pulsed light in Meibomian Gland Dysfunction in 50 participants. Status unknown.
30 July 2021
Quick facts
| Lead sponsor | Dar Al Shifa Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 1 December 2020 |
| Primary completion | 30 July 2021 |
| Estimated completion | 30 July 2021 |
| Sites | 1 location across Kuwait |
Drugs / interventions tested
- intense pulsed light
Conditions studied
- Meibomian Gland Dysfunction — all drugs for Meibomian Gland Dysfunction →
Sponsor
Dar Al Shifa Hospital
Who can join
20 and older, any sex, with Meibomian Gland Dysfunction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
to evaluate the effect of intense pulsed light on resistant patients with Meibomian gland dysfunction
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04904874
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of intense pulsed light
Trials testing the same drug.
- NCT06655129 — Intense Pulsed Light (IPL) Medical Device as Treatment for Patient Suffering From Skin Disorder · NA · recruiting
- NCT03658811 — Intense Pulse Light Treatment With Meibomian Gland Expression of the Upper Eyelids in Dry Eye Disease · NA · completed
Other recruiting trials for Meibomian Gland Dysfunction
Currently open trials in the same condition.
- NCT06220474 — Therapeutic Efficacy and Safety of Non-Invasive RF Treatment in Refractory MGD · NA · recruiting
- NCT06371300 — Photobiomodulation With REd vs BluE Light (REBEL) · NA · recruiting
- NCT06054217 — Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex · Phase 2 · active not recruiting
- NCT03652337 — Meibomian Gland Dysfunction Management · NA · active not recruiting
Other Dar Al Shifa Hospital trials
Trials by the same sponsor.
- NCT04904887 — Clinical Outcomes With a New Monofocal IOL Enhanced for Intermediate Vision · NA · unknown
- NCT04907955 — Visual Performance Following Implantation of Presbyopia Correcting IOLs · NA · completed
- NCT03288116 — Objective and Subjective Diagnostic Parameters in the Fellow Eye of Unilateral Keratoconus · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04904874 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dar Al Shifa Hospital
- Last refreshed: 27 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04904874.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing